CAR T-cell therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma. However, its effectiveness in solid tumors is still being researched. This therapy involves extracting a patient's T-cells, modifying them to express chimeric antigen receptors (CARs) that target specific cancer cells, and then infusing them back into the patient. Despite its potential, CAR T-cell therapy can cause severe side effects, including cytokine release syndrome and neurological toxicity.
